Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 22Endocrine 12NET 10Genitourinary 10Tumor-Agnostic 7Gynecologic 6Gastrointestinal 6CNS 6Sarcoma 5Other hematologic neoplasm 3Thoracic 2Plasma cell 2Lymphoid 2Head & Neck 2Dermatologic 2Other solid neoplasm 1Myeloid 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Everolimus × Lymphoid × 1 year × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
45 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡